Generic drugmaker Mylan Inc. (MYL) said Wednesday that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Zolmitriptan tablets, 2.5 mg and 5 mg.
The product is the generic version of IPR Pharmaceuticals Inc.'s Zomig Tablets and is indicated for the acute treatment of migraine with or without aura in adults.
Zolmitriptan tablets are for use only where a clear diagnosis of migraine has been established. If a patient does not respond after the first dose, a healthcare provider should reconsider the diagnosis before re-administering. The product is not indicated for the prevention of migraine attacks or cluster headaches.
Zolmitriptan Tablets, 2.5 mg and 5 mg, had U.S. sales of about $152.8 million for the 12 months ending March 31, 2013, according to IMS Health. Mylan said it has begun shipping the product.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.